CDC recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC).MMWR CDC Surveill Summary1995; 44(No. RR-12).
3.
Staphylococcus aureus with reduced susceptibility to vancomycin — United States, 1997.MMWR Morb Mortal Weekly Rep1997; 46: 765–6.
4.
VasS.I.VRE and empirical vancomycin for CAPD peritonitis: use at your own/patient's risk.Perit Dial Int1998; 18: 86–7.
5.
Van BiesenW., VanholderR., VogelaersD., PelemanR., VerschraegenG., VijtD.The need for a center-tailored treatment protocol for peritonitis.Perit Dial Int1998; 18: 274–81.
6.
AlvesF.R., DantasR.C.Is the treatment of beta lactam sensitive infections (BLSI) without vancomycin (Vc) possible (Abstract)?Perit Dial Int1997; 17(Suppl 1): S27.
7.
LaiM.N., KaoM.T., ChenC.C., CheungS.Y., ChungW.K.Intraperitoneal once-daily dose of cefazolin and gentamicin for treating CAPD peritonitis.Perit Dial Int1997; 17: 87–9.
8.
VasS., BargmanJ., OreopoulosD.G.Treatment in PD patients of peritonitis caused by gram-positive organisms with single daily dose of antibiotics.Perit Dial Int1997; 17: 91–4.
9.
WeberJ., StaerzE., MettangT., MachleidtC., KuhlmannU.Treatment of peritonitis in continuous ambulatory peritoneal dialysis (CAPD) with intraperitoneal cefazolin and gentamicin.Perit Dial Int1989; 9: 191–5.
10.
GolperT.Intermittent versus continuous antibiotics for PD-related peritonitis.Perit Dial Int1997; 17: 11–12.
11.
BunkeC.M., BrierM.E., GolperT.A.Outcomes of single organism peritonitis in peritoneal dialysis: gram negatives versus gram positives in the Network 9 Peritonitis Study.Kidney Int1997; 52: 524–9.
12.
SandoeJ.A.T., GokalR., StruthersJ.K.Vancomycin-resistant enterococci and empirical vancomycin for CAPD peritonitis.Perit Dial Int1997; 17: 617–18.